Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Mar 23, 2014 1:53pm
147 Views
Post# 22357413

RE:RE:RE:RE:RVX - Managing Perceptions

RE:RE:RE:RE:RVX - Managing PerceptionsHi Jkj.

Excellent point and great for Pat.

A few ideas.
  1. I think that repetition of the Feb webcast in bullet points may help - e.g. -2% point plaque reduction in low HDL high CVD patients, regression achieved in very short time period (6 weeks), increased HDL-P (the more accurate measure for the good cholesterol), no liver damage, AND significantly reduced MACE (hence a possibility of trial acceleration and movement to the market). There may be other bullet points but I can't remember them.
  2. Market potential of $14,000,000,000 in the USA alone and double that including expanded markets.
  3. The fact that Crestor will be losing it's patent protection and that rvx-208 can work with the generic statins.
  4. Reposting on venture capital websites.
  5. Posting on websites that may cater to those with CVD.

I'm sure others will have better ideas and the opportunity to spread the good news seems huge.

Keep the good news flowing. Those post hoc results are incredible and with very low p values (i.e. not just random chance).
Cheers
Toinv
Bullboard Posts